Cancer immunotherapy drugs are by far the fastest-growing segment of the oncology drugs industry.
multimmune GmbH's fight against cancer theranostics programs has been supported by investment from a number of sources:
- Technology Investment Fund Bayern III GmbH & Co. KG
- S-Refit AG
- Raabe Verögensverwaltungs GmbH
- Ventac Partners GmbH
- Private Investors
If you would like to participate in our exciting programmes and share our success, then please review our Investment Opportunities below.
multimmune GmbH is offering a number of innovative funding opportunities for investors to support, and engage with, the timely development and targetted translational delivery and exploitation of its pipeline THERAPEUTICS, DIAGNOSTICS and IMAGING platforms.